{"id":"NCT02089113","sponsor":"Ocular Therapeutix, Inc.","briefTitle":"OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery","officialTitle":"A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase 3B Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-01","completion":"2015-03","firstPosted":"2014-03-17","resultsPosted":"2016-03-30","lastUpdate":"2019-09-26"},"enrollment":241,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Post-Surgical Ocular Pain","Post-Surgical Ocular Inflammation"],"interventions":[{"type":"DRUG","name":"Dexamethasone","otherNames":[]},{"type":"PROCEDURE","name":"Placebo Vehicle","otherNames":[]}],"arms":[{"label":"OTX-DP","type":"EXPERIMENTAL"},{"label":"PV","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who had undergone cataract extraction with intraocular lens implantation","primaryOutcome":{"measure":"Number of Participants With an Absence of Anterior Chamber Inflammation","timeFrame":"Day 14","effectByArm":[{"arm":"OTX-DP","deltaMin":63,"sd":null},{"arm":"Placebo Vehicle","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":160},"commonTop":[]}}